Research programme: ribosomal S6 kinase inhibitors - Luna InnovationsAlternative Names: RSK inhibitors - Luna Innovations
Latest Information Update: 16 Jul 2016
At a glance
- Originator University of Virginia
- Developer Luna Innovations
- Mechanism of Action Ribosomal protein S6 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Infections in USA
- 20 Jun 2008 Preclinical trials in Infections in USA (unspecified route)